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Summary  The  right  ventricle  (RV)  has  to  face  major  changes  in  loading  conditions  due  to  car-
diovascular  diseases  and  pulmonary  vascular  disorders.  Clinical  experience  supports  evidencePulmonary
hypertension;
Pulmonary
circulation;
that the  RV  better  compensates  for  volume  than  for  pressure  overload,  and  for  chronic  than
for acute  changes.  For  a  long  time,  right  ventricular  (RV)  pathophysiology  has  been  restricted
to patterns  extrapolated  from  left  heart  studies.  However,  the  two  ventricles  are  anatomi-
cally, haemodynamically  and  functionally  distinct.  RV  metabolic  properties  may  also  result  in
Abbreviations: AT, angiotensin; Ea, arterial elastance; Ees, end-systolic elastance; IVA, acceleration of the myocardium during isovolumic
contraction; LV, left ventricle/ventricular; MHC, myosin heavy chain; PA, pulmonary arterial; PH, pulmonary hypertension; PVR, pulmonary
vascular resistance; RAAS, renin-angiotensin-aldosterone system; RV, right ventricle/ventricular; RVF, right ventricular failure; RVFAC, right
ventricular fractional area change; RVMPI, right ventricular myocardial performance index; SVI, stroke volume index; TAPSE, tricuspid
annular plane systolic excursion.
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a  different  behaviour  in  response  to  pathological  conditions  compared  with  the  left  ventricle.
In this  review,  current  knowledge  of  RV  pathophysiology  is  reported  in  the  setting  of  chronic
pressure  overload,  including  recent  experimental  ﬁndings  and  emerging  concepts.  After  a  time-
varying compensated  period  with  preserved  cardiac  output  despite  overload  conditions,  RV
failure ﬁnally  occurs,  leading  to  death.  The  underlying  mechanisms  involved  in  the  transition
from compensatory  hypertrophy  to  maladaptive  remodelling  are  not  completely  understood.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  ventricule  droit  (VD)  fait  face  à  d’importantes  variations  de  ses  conditions  de
charge en  réponse  aux  maladies  cardiovasculaires  et  pathologies  vasculaires  pulmonaires.  Le
VD supporte  mieux  une  surcharge  de  volume  qu’une  surcharge  de  pression,  de  même  il  s’adapte
mieux aux  variations  progressives  qu’aux  changements  aigus.  La  physiopathologie  du  VD  a  pen-
dant longtemps  été  résumée  à  des  extrapolations  de  la  physiopathologie  du  ventricule  gauche.
Cependant  les  deux  ventricules  sont  différents,  tant  sur  le  plan  anatomique,  hémodynamique
que fonctionnel.  Les  caractéristiques  métaboliques  singulières  du  VD  peuvent  également  être
à l’origine  d’une  adaptation  différente  aux  conditions  pathologiques.  Après  une  longue  période
compensatrice  avec  préservation  du  débit  cardiaque,  la  dysfonction  du  VD  s’installe  ﬁnale-
ment face  à  la  surcharge  chronique  persistante.  Les  mécanismes  impliqués  dans  la  transition
depuis l’hypertrophie  compensatrice  jusqu’au  remodelage  inadapté  sont  méconnus.  Dans  cette
revue, les  connaissances  actuelles  de  la  physiopathologie  du  VD  dans  l’hypertension  pulmonaire
chronique  sont  reportées  à  partir  des  résultats  récents  issus  de  la  recherche  expérimentale.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Rackground
ight  heart  failure  is  commonly  related  to  left  ventricu-
ar  (LV)  dysfunction.  Ischaemic  myocardial  injury  or,  less
requently,  arrhythmogenic  dysplasia  of  the  right  ventricle
RV),  congenital  heart  disease  and  chronic  respiratory  dis-
ase,  including  pulmonary  vascular  disorders,  can  also  result
n  right  ventricular  failure  (RVF).  RVF  is  also  a  current  prob-
em  in  the  post-operative  course  of  heart  transplantation
nd  LV  assist  device  implantation  [1,2].  In  pulmonary  hyper-
ension  (PH),  pulmonary  vascular  damage  will  inevitably
ffect  the  whole  cardiopulmonary  unit  [3].  It  has  been
ppreciated  over  the  last  two  decades  that  right  ventricular
RV)  dysfunction  is  the  most  important  determinant  of  long-
erm  outcomes  in  PH  patients.  Actually,  prolonged  survival
s  related  more  to  RV  function  than  to  pulmonary  haemody-
amics  per  se.  In  studies  addressing  haemodynamic  variables
nd  survival  in  PH,  high  mean  right  atrial  pressures  and  low
ardiac  output  are  consistently  associated  with  poorer  sur-
ival  [4—6].  Despite  major  improvements  in  pharmacological
anagement  over  the  last  15  years,  PH  patients  still  die  from
VF.
RV  pathophysiology  has  been  overlooked  for  many  years.
n  the  past,  several  experiments  relegated  the  RV  to  a
assive  conduit,  suggesting  that  the  RV  pump  might  be
eglected.  For  example,  Starr  et  al.  showed  that  elec-
rocautery  ablation  of  the  RV  free  wall  in  dogs  was  not
ssociated  with  signiﬁcant  changes  in  haemodynamics,  and
hat  all  animals  survived  [7].  For  a  long  time,  the  Fontan  pro-
edure  also  supported  the  clinical  evidence  that  RV  absence
s
r
t
iid  not  compromise  overall  heart  function  [8].  Physicians
ave  recently  shown  clinical  interest  in  the  right  heart,  as
V  function  appears  to  be  a  prognostic  factor  in  left  heart
ailure,  PH  and  other  chronic  respiratory  disorders.  Most
f  mechanisms  involved  in  left  heart  diseases  were  ﬁrst
xtrapolated  to  RV  pathophysiology,  despite  the  two  ventri-
les  differing  in  their  embryology,  geometry  and  physiology
9,10].  Recently,  a  new  focus  on  RVF  has  emerged,  which
ims  to  improve  both  understanding  and  clinical  manage-
ent.  In  PH,  there  are  different  phenotypic  abnormalities
n  the  RV.  Surprisingly,  some  patients  share  the  same  phe-
otype,  whereas  the  RV  is  not  exposed  to  the  same  degree
f  pressure  overload  [11]. Considering  the  central  role  of
he  RV  in  cardiopulmonary  diseases,  Mehra  et  al.  suggested
 comprehensive  nomenclature  of  right  heart  failure,  based
n  aetiology,  anatomical  injury,  pathophysiology  and  func-
ional  status  [12]. Experimentally,  major  efforts  have  been
ade  to  improve  our  understanding  of  RV  remodelling.  Sev-
ral  animal  models  of  chronic  RVF  have  thus  been  reported
ver  the  last  decade  to  reproduce  the  main  features  of  RV
ysfunction  [13].
The  mechanisms  of  RVF  as  well  as  the  clinically  relevant
ariables  for  measuring  RV  function  in  PH  are  still  being
ebated.  In  this  paper,  after  a  brief  description  of  the  nor-
al  RV,  we  ﬁrst  seek  to  overview  the  functional  evaluation  of
V  contractility  and  reserve  in  the  setting  of  chronic  pres-
ure  overload.  We  then  present  current  knowledge  of  RV
emodelling  related  to  PH.  Based  on  experimental  ﬁndings,
he  cellular  mechanisms  and  molecular  pathways  involved
n  the  transition  from  compensated  RV  hypertrophy  to
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pRight  ventricular  pathophysiology  in  chronic  pressure  overlo
dysfunction  and  failure  are  discussed.  Finally,  recent  thera-
peutic  approaches  for  the  failing  RV  are  considered.  Isolated
ex  vivo  studies  of  the  RV  will  not  be  considered  in  this  review.
The normal RV: embryology, morphology
and  physiology
The  RV  does  not  originate  from  the  primary  heart  ﬁeld,
unlike  the  left  ventricle  (LV).  Recent  experiments  have
shown  that  the  RV  does  not  share  the  same  origin  as  the  LV,
emphasizing  the  need  for  a  speciﬁc  comprehensive  approach
to  each  ventricle  [14—17].  The  RV  actually  originates  from
the  secondary  heart  ﬁeld,  while  the  atrium  and  the  LV
develop  from  the  primary  heart  ﬁeld.  Three  separate  cham-
bers  can  be  described  in  the  RV:  the  sinus  or  inlet,  which
consists  of  the  tricuspid  valve,  chordae  tendineae  and  pap-
illary  muscles;  the  trabeculated  apical  myocardium;  and  the
infundibulum  or  conus  [10].  Compared  with  the  LV,  the  RV
has  a  crescent  shape,  with  a  higher  capacity  and  a  lower
myocardial  mass.
In  utero  the  RV  wall  is  thick  because  the  pulmonary
vascular  resistance  (PVR)  is  high.  At  birth,  PVR  decreases
dramatically,  leading  to  high  compliance,  resulting  from  pro-
gressive  thinning  of  the  RV  free  wall  [10].  RV  contraction
can  be  understood  as  a  three-step  motion.  The  tricuspid
annulus  ﬁrst  moves  toward  the  apex,  then  the  apex  moves
toward  the  infundibulum.  The  radial  contraction  of  the  RV
free  wall  towards  the  interventricular  septum  is  the  third
and  minor  component  of  RV  contractility;  it  results  from
marked  shrinking  of  the  deep  muscle  ﬁbres.  This  myoﬁbre
layer  is  continuous  between  the  LV  and  the  RV;  it  repre-
sents  one  of  the  three  anatomical  elements  of  ventricular
interdependence,  along  with  the  pericardium  and  the  inter-
ventricular  septum,  explaining  why  the  LV  is  involved  in  RV
contraction  (from  20%  to  40%  of  RV  contractile  performance)
[10].
The  RV  is  exposed  to  frequent  changes  in  venous  return,
inﬂuenced  by  respiratory  variations,  by  the  supine  or  ortho-
static  position  of  the  body  and  by  pathological  disorders
affecting  ﬁlling  conditions.  The  RV  is  highly  distensible
because  of  its  larger  shape  and  four  times  thinner  free  wall
compared  with  the  LV.  The  RV  is  therefore  known  to  adapt
much  better  to  chronic  volume  overload  than  to  pressure
overload  [18].  An  increase  in  preload  has  been  demonstrated
to  improve  myocardial  contraction  in  the  left  heart  [19].
The  Frank—Starling  mechanism  characterizes  the  increase  in
ventricular  stroke  work  in  response  to  wall  stress  enhance-
ment.  Because  of  a  weak  relationship  between  surface  area
and  ventricular  volume,  the  preload  recruitable  stroke  work
is  moderate  in  the  physiological  RV.  The  Frank—Starling
mechanism  may  only  improve  ventricular  contraction  in  case
of  signiﬁcant  enlargement  of  the  RV  [18].  On  the  other  hand,
excessive  volume  loading  may  be  detrimental  to  the  RV,
because  of  acute  impairment  of  coronary  ﬂow  within  the
RV  free  wall  [20].
RV afterload  is  deﬁned  by  pulmonary  vascular  load.  The
pulmonary  vasculature  is  characterized  by  a  low  resistance
and  high  compliance  proﬁle.  PVR  is  usually  linked  to  RV
afterload  in  normal  conditions  because  of  easy  assessment
in  clinical  practice.  However,  PVR  only  accounts  for  the
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esistive  component  of  the  pulmonary  vascular  load;  as
 result,  PVR  underestimates  RV  afterload  by  neglecting
lood  ﬂow  pulsatility  and  wave  reﬂections  through  the  pul-
onary  vasculature.  Most  pulmonary  vascular  diseases  are
nown  to  disturb  both  components  of  the  pulmonary  vascu-
ar  load.  Pulmonary  arterial  impedance  is  probably  the  most
omplete  measure  of  the  pulmonary  vascular  load.  Input
mpedance  actually  includes  both  static  and  dynamic  com-
onents  of  RV  afterload,  and  it  may  be  a  better  predictor  of
ong-term  outcomes  in  PH  than  PVR  alone  [21];  its  deﬁnition
n  the  frequency  domain  is,  however,  restrictive  for  wide
linical  use.  Sunagawa  et  al.  characterized  the  systemic
rterial  load  in  the  time  domain  as  effective  arterial  elas-
ance  (Ea)  [22].  Ea  is  deﬁned  as  the  change  in  pressure  for  a
hange  in  volume,  and  can  therefore  be  linked  to  the  effec-
ive  arterial  load  that  the  ventricle  has  to  overcome  during
jection.  Pulmonary  Ea  can  be  determined  using  pressure-
olume  loops  analysis  or  estimated  as  the  ratio  of  stroke
olume  to  end-systolic  pressure.
ssessment of RV pump function: the
mportance of RV-PA coupling
s  RV  function  is  the  main  determinant  of  survival  in  several
ardiopulmonary  diseases,  there  is  major  interest  in  inves-
igating  the  right  heart.  Echocardiography  is  the  mainstay
n  the  assessment  of  RV  function.  The  main  limitation  is  the
oad  dependency  of  most  of  these  noninvasive  indices.  The
V  is  optimally  matched  to  pulmonary  vascular  load  in  the
ormal  state.  Afterload  mismatch  appears  to  be  the  most
mportant  prognostic  factor  for  RV  systolic  dysfunction  in
ressure  overload  conditions  [23]. Ventricular-arterial  cou-
ling  is  an  important  determinant  of  cardiac  performance
nd  energetics;  it  reﬂects  maximal  efﬁciency  between
ydraulic  work  production  and  myocardial  oxygen  con-
umption.  RV-pulmonary  arterial  (RV-PA)  coupling  can  be
uantiﬁed  in  real  time,  using  pressure-volume  loops  analy-
is,  as  the  ratio  of  the  RV  end-systolic  elastance  (Ees)  to  the
a  (Fig.  1).  Ees  is  deﬁned  as  the  slope  of  the  end-systolic
ressure-volume  linear  relationship  obtained  by  changes  in
entricular  ﬁlling  [24,25].  To  be  load-independent,  this  end-
ystolic  relationship  is  studied  during  transient  occlusion  of
he  inferior  vena  cava,  so  that  Ees  is  currently  considered
o  be  the  most  reliable  measure  of  ventricular  contractility.
Despite  signiﬁcant  interspecies  differences  in  basal  pul-
onary  haemodynamics,  Wauthy  et  al.  showed  that  Ees/Ea
hanges  similarly,  secondary  to  RV  pressure  overload,  in  dif-
erent  animal  species  [26].  Furthermore,  RV  adaptation  to
hanges  in  loading  conditions  is  relatively  preserved  through
ammalian  spontaneous  evolution  [26].  Ranges  of  usual  RV-
A  coupling  values  among  animal  species  are  summarized
n  Table  1.  Impairment  of  RV-PA  coupling  is  reﬂected  in  an
es/Ea  ratio  of  <  1  in  large  animals,  whereas  the  normal
es/Ea  ratio  ranges  from  0.5  to  0.8  in  rodents.  At  the  early
tage  of  RV  pressure  overload,  Ees  is  often  increased  to  com-
ensate  for  the  elevated  afterload  [27,28]. However,  RV-PA
oupling  may  be  decreased  at  that  time,  without  RV  dysfunc-
ion  at  rest.  This  is  related  more  to  an  increase  in  Ea  than  to
 signiﬁcant  decrease  in  Ees.  When  contractile  performance
ecomes  insufﬁcient  to  overcome  the  elevated  afterload,
522  J.  Guihaire  et  al.
Table  1  Right  ventricular  and  pulmonary  arterial  elastances  and  ventricular-arterial  coupling  values  among  animal
species  in  normal  loading  conditions.
Animals  Weight  (kg)  Methodsa Ees  (mmHg/mL)  Ea  (mmHg/mL)  Ees/Ea
Rat  [75]  0.20—0.25  Conductance  82  ±  53  150  ±  60  0.53  ±  0.2
Mouse  [76]  0.02—0.04  Admittance  1.8  ±  0.5  2.7  ±  1.2  0.71  ±  0.27
Dog  [77]  25  Single-beat  1.11  ±  0.07  1.0  ±  0.06  1.13  ±  0.08
Goat  [26]  24  Single-beat  2.0  ±  0.4  1.3  ±  0.1  1.7  ±  0.3
Piglet  [78] 5.7—6.1 Single-beat  1.45  ±  0.08  0.91  ±  0.07  1.62  ±  0.09
Pig  [79] 20—25 Single-beat  1.4  ±  0.2 0.9  ±  0.1  1.4  ±  0.4
Ea: pulmonary arterial elastance; Ees: right ventricular end-systolic elastance.
a Methods of recording pressure-volume loops were speciﬁed as conductance or admittance catheterization, or as single-beat elastance.
Figure 1. Pressure-volume loops in the right ventricle.
A. Schematic conductance catheterization of the right ventri-
cle (RV). B. Example of pressure-volume loops in the normal RV;
transient occlusion of the inferior vena cava reduces right ventric-
ular preload, leading to progressive decrease of right ventricular
stroke volume. Ea: arterial elastance; Ees: end-systolic elastance;
RA: right artery.
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aV  stroke  volume  and  RV  ejection  fraction  decrease.  RV
ilatation  and  adverse  remodelling  then  occur,  leading  to
VF  [27,29].
The  concept  of  ventricular-arterial  coupling  is  not  com-
only  used  in  clinical  practice,  mainly  because  it  requires
nvasive  and  time-consuming  measurement.  Considerable
fforts  have  been  made  to  estimate  the  contractile  per-
ormance  of  the  RV  from  measurement  of  RV  pressure  and
olume.  Single-beat  elastance  is  a  promising  method  val-
dated  recently  in  clinical  practice  for  the  assessment  of
V  elastance  without  dramatic  changes  in  loading  condi-
ions,  using  cardiac  magnetic  resonance  imaging  for  volume
ssessment  [30—32].  Several  echocardiography  indices  of  RV
unction  have  been  further  reported  to  characterize  the
ystole,  such  as  tricuspid  annular  plane  systolic  excursion
TAPSE),  RV  fractional  area  change  (RVFAC),  RV  myocardial
erformance  index  (RVMPI),  stroke  volume  index  (SVI)  and,
ore  recently,  acceleration  of  the  myocardium  during  isovo-
umic  contraction  (IVA)  [33—36].  Of  all  these  indices,  Vogel
t  al.  showed  that  IVA  may  be  the  most  relevant  for  RV
ontractility  [33—36]. There  were  two  main  limitations  to
his  study.  First,  IVA  (as  well  as  TAPSE,  RVFAC  and  RVMPI)
s  strongly  load  dependent,  and  thus  may  not  accurately
eﬂect  RV  pump  function.  Second,  this  study  validated  IVA
s  a  contractility  index  for  the  RV  in  a  ‘healthy’  animal
odel,  not  in  the  setting  of  chronic  RV  remodelling  caused
y  either  pressure  or  volume  overload.  We  recently  showed
n  a  piglet  model  of  chronic  pressure  overload  for  the  RV,
hat  usual  noninvasive  measures  of  RV  systolic  function  were
ore  strongly  associated  with  RV-PA  coupling  than  with  con-
ractility  (Ees).  Despite  a  marked  improvement  in  Ees,  RV
ystolic  dysfunction  was  observed,  with  a  marked  decrease
n  TAPSE,  RVFAC  or  RVMPI.  This  is  in  accordance  with  our
ypothesis  that  commonly  used  indices  of  RV  function  do  not
ppear  to  be  speciﬁc  for  RV  contractility,  but  rather  reﬂect
he  interaction  between  RV  pump  function  and  pulmonary
ascular  load  [28]. However,  the  best  way  to  assess  contrac-
ile  performance  for  the  overloaded  RV  is  still  a  matter  of
ebate.
Clinical  series  in  PH  have  highlighted  that  changes  in  RV
unction  —  rather  than  changes  in  pulmonary  pressure  or
VR  —  affect  long-term  survival  dramatically  [37].  Impair-
ent  of  RV  contractility  in  both  longitudinal  and  transverse
lanes  is  often  observed  at  an  advanced  stage  in  the  over-
oaded  RV.  This  functional  assessment  is  routinely  performed
t  rest,  whereas  exercise  capacity  is  a  strong  predictor
ad  523
Table  2  Cellular  and  molecular  changes  involved  in
right  ventricular  maladaptive  remodelling.
Cardiac  myocyte  ↑  Length  and  cross-sectional  area
↑  Apoptosis
↑  Necrosis
Extracellular
matrix
↑  Collagen  synthesis;  ↓  collagen
degradation
↓  Capillary  density
↑ Rate  of  mast  cells;  ↑  rate  of
TNF-
Contractility  ↓  -MHC;  ↑  -MHC;  ↑  -SMA
↓  SERCA-2
Mitochondrial
metabolism
Glycolytic  shift
Oxidative  stress  Failure  in  antioxidative  defence
Neurohormonal
modulation
↓  -adrenergic  receptor  density
↑  AT  II  receptor  type  1  density
Impairment  of  AT  II  receptor  type  1
signalling  pathway
AT: angiotensin; MHC: myosin heavy chain; SERCA-2: sarcoplas-
mic endoplasmic reticular calcium adenosine triphosphatase 2;
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of  long-term  outcome  in  cardiopulmonary  diseases.  RV
contractile  reserve  has  been  poorly  reported.  Grunig  et  al.
recently  suggested  that  exercise-induced  pulmonary  artery
systolic  pressure  increase  could  estimate  RV  contractile
reserve,  and  may  be  a  prognostic  factor  in  PH  [38].  Pharma-
cological  stress  using  dobutamine  infusion  is  better  adapted
to  heart  failure  patients  than  exercise  testing,  especially
for  echocardiography  Doppler  measurements  during  stress.
Sharma  et  al.  recently  studied  RV  reserve  using  low-dose
dobutamine  stress  echocardiography  in  PH  patients  [39].
Contractile  reserve  for  the  RV  was  quantiﬁed  as  any  signiﬁ-
cant  changes  in  TAPSE  and  tricuspid  annular  systolic  velocity
(S′).  The  protocol  was  well  tolerated  in  PH  patients.  This
study  showed  that  RV  reserve  was  impaired  in  PH  patients,
even  in  those  who  displayed  normal  RV  function  at  rest.
Dobutamine  stress  may  reveal  early  RV  dysfunction  in  the
setting  of  chronic  pressure  overload.  These  ﬁndings  are
in  accordance  with  our  experimental  results.  We  recently
reported  that  dobutamine-induced  relative  changes  in  RV
stroke  volume  index  (SVI)  and  Ees  were  lower  in  piglets
exposed  to  chronic  pressure  overload.  RV  reserve,  deﬁned
as  any  change  in  SVI  during  pharmacological  stress,  was
strongly  associated  with  resting  ventricular-arterial  coupling
in  this  study  [40].  It  could  be  a  promising  predictive  measure
for  estimating  RV  response  to  therapy,  as  well  as  a  prognos-
tic  marker,  as  long-term  survival  is  strongly  associated  with
the  ability  of  the  RV  to  durably  face  the  elevated  afterload.
Molecular and cellular correlates of RV
remodelling in chronic pressure overload
Examination  of  animal  models  provides  insight  into  RV  pro-
gressive  remodelling,  from  compensated  hypertrophy  to
maladaptive  enlargement  and  failure.  Most  pathways  have
been  observed  previously  in  LV  failure.  A  better  understand-
ing  of  RVF  pathophysiology,  especially  during  the  transition
from  adaptive  hypertrophy  to  the  decompensated  state,
is  needed  to  ﬁnd  new  therapeutic  targets.  Cellular  and
molecular  changes  suggested  to  determine  RV  maladaptive
remodelling  are  summarized  in  Table  2.
Local  and  systemic  activities  of  the  renin-angiotensin-
aldosterone  system  (RAAS)  are  involved  in  RV  structural  and
functional  changes.  Even  if  neurohormonal  modulation  is
beneﬁcial  at  the  early  stage,  persistent  adrenergic  over-
stimulation  and  upregulation  of  the  RAAS  are  associated
with  disease  progression  and  mortality  in  PH  patients  [41].
Angiotensin  II  (AT  II)  signiﬁcantly  impacts  on  myocardial
remodelling.  Rouleau  et  al.  observed  that  RV  chronic  pres-
sure  overload  resulted  in  AT  II  receptors  uncoupling  in  a
compensated  RV  hypertrophy  rabbit  model.  This  impairment
of  the  RAAS  signalling  pathway  led  to  adverse  contractility
performance,  but  could  be  efﬁciently  reversed  after  admin-
istration  of  the  angiotensin-converting  enzyme  inhibitor
ramipril  [42].  Systemic  and  myocardial  elevated  rates  of
AT  II  may  induce  cardiomyocyte  hypertrophy  and  contrac-
tile  dysfunction.  Fibrosis  secondary  to  inhibition  of  collagen
degradation  and,  to  a  lesser  extent,  extracellular  matrix
inﬂammation  have  also  been  related  to  an  increased  level  of
AT  II  [43].  These  adverse  effects  are  supported  by  the  cardio-
protective  action  of  RAAS  blockage.  Angiotensin-converting
d
a
p
iSMA: smooth muscle actin; TNF: tumour necrosis factor.
nzyme  inhibitors  and  AT  II  type  1  receptor  blockers  have
een  demonstrated  to  decrease  RV  expression  of  collagen
ype  I  and  type  III  in  rodents  [44,45].
Transition  from  RV  compensated  state  to  RVF  results
ot  only  from  cardiomyocyte  dysfunction,  but  also  from
dverse  remodelling  of  the  extracellular  matrix.  Under  per-
istent  overload  conditions,  extracellular  matrix  changes
ay  lead  to  RV  dysfunction.  Increasing  rates  of  myocardial
brosis  have  been  reported  in  RVF  models,  as  previously
emonstrated  in  PH  patients,  whereas  only  a  minimal
egree  of  ﬁbrosis  is  observed  in  compensated  RV  hyper-
rophy  [43,46]. Increased  collagen  synthesis  occurs  early  in
he  setting  of  RV  wall  stress  enhancement.  This  upregula-
ion  at  both  transcriptional  and  post-transcriptional  levels
ncreases  dramatically  during  the  ﬁrst  week  of  pressure
verload  conditions,  and  decreases  thereafter.  However,
he  collagen  production  rate  still  remains  higher  than  in
he  normal  RV  because  of  a  decreased  degradation  process
47]. In  monocrotalline  rats,  Lamberts  et  al.  suggested  that
ncreased  collagen  content  in  the  myocardium  may  be  the
ost  important  structural  change  before  RV  dysfunction  in
he  setting  of  chronic  pressure  overload  [48].
Recent  animal  and  human  studies  support  the  growing
vidence  that  inﬂammation  plays  a  key  role  in  heart  fail-
re  pathophysiology.  An  increased  rate  of  production  of
umour  necrosis  factor  alpha  can  impair  systolic  function
n  left  heart  failure  [49]. If  neutrophils  are  found  in  the
V  myocardium  early  after  acute  increase  in  afterload,
acrophages  may  be  involved  in  progressive  remodelling
econdary  to  chronic  PH  [50].  We  recently  showed  in  a
at  model  of  RV  dysfunction  that  macrophage  inﬁltration
f  the  myocardium  was  strongly  associated  with  systolic
ysfunction  characterized  by  signiﬁcant  decreases  in  TAPSE
nd  RVFAC  [51].  The  precise  role  of  macrophages  in  the
athophysiology  of  right  heart  failure  needs  to  be  further
nvestigated.
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Reversion  to  foetal  phenotype  occurs  during  RV  hyper-
rophy  in  response  to  chronic  pressure  overload.  Thompson
t  al.  found  foetal  gene  re-expression  within  the  RV
yocardium  in  response  to  pulmonary  artery  banding
n  cats.  Upregulation  of  Nkx2-5  transcription  factor  was
bserved,  which  is  usually  only  expressed  in  the  growing
eart.  However,  the  precise  function  of  this  transcription
actor  is  unknown  [52].  A  decrease  in  ˛-myosin  heavy  chain
MHC)  gene  expression  and  protein  synthesis  results  in  a
ompensatory  increase  in  -MHC  [46].  This  adaptive  phe-
otype  provides  a  lower  energetic  cost  proﬁle  to  the  failing
yocardium,  as  -MHC  is  usually  involved  in  stronger  and
aster  contractions,  whereas  -MHC  accounts  for  lower
ontractile  potential.  We  reported  in  our  piglet  model  of
hronic  PH  that  ventricular-arterial  uncoupling  was  strongly
ssociated  with  upregulation  of  -MHC  expression.  We  sug-
ested  that  dynamic  changes  in  myosin  expression  over
ime  may  determine  RV  work  efﬁciency  [53].  Foetal  -MHC
xpression  may  be  associated  with  a  metabolic  shift  from
atty  acid  to  glucose  oxidation  [54].  As  described  in  solid
umours,  suppression  of  the  mitochondrial  oxidative  func-
ion  has  been  shown  in  the  RV  myocardium  exposed  to
hronic  pressure  overload  [55].  If  mitochondrial  structural
hanges  are  observed  in  RV  remodelling  (defects,  differ-
nt  shape  and  size),  they  have  not  been  well  correlated
ith  the  severity  of  RV  dysfunction  [43].  Hibernation  mito-
hondrial  metabolism  seems,  however,  to  be  involved  in  the
ransition  from  compensated  RV  hypertrophy  to  maladap-
ive  remodelling.  The  glycolytic  phenotype  resulting  in  RV
ysfunction  is  associated  with  impaired  mitochondrial  elec-
rical  potential,  as  illustrated  by  an  increased  uptake  of
-18  ﬂuorodeoxyglucose  on  positron  emission  tomography
maging  [56].  This  maladaptive  metabolism  can  be  reversed
y  a  pyruvate  dehydrogenase  kinase  inhibitor,  dichloroac-
tate,  leading  to  an  increase  in  pyruvate  concentration  in
he  mitochondria  [56].
RV  ischaemia  is,  furthermore,  known  to  play  a key  role
n  the  haemodynamic  collapse  related  to  acute  severe  pres-
ure  overload.  Ischaemia  has  been  reported  to  induce  RV
ysfunction  in  experimental  acute  PH  because  of  compres-
ion  of  coronary  vessels,  resulting  from  elevated  myocardial
tretch.  A  loss  of  coronary  vasodilatation  reserve  could  also
xacerbate  RV  contractility  decline  in  these  conditions  [57].
hether  ischaemia  is  involved  in  the  transition  from  com-
ensated  RV  hypertrophy  to  maladaptive  remodelling  and
ailure  is  still  a  matter  of  debate  in  the  overloaded  RV.  At
n  early  stage,  RV  pressure  overload  may  result  in  signif-
cant  changes  in  coronary  perfusion  because  of  increased
all  stress,  especially  during  systole  [58,59].  RV  ischaemia
as  been  investigated  in  PH  patients  without  coronary  artery
tenosis.  Signiﬁcant  perfusion  defects  were  found  in  a  small
roup  of  primary  PH  patients  using  myocardial  technetium-
9m  scintigraphy,  but  they  were  not  correlated  with  RV
ysfunction  severity  [60].  Many  authors  think  that  myocar-
ial  ischaemia  could  be  involved  in  the  development  of
VF.  Recent  experimental  studies  demonstrated  that  RV  cap-
llary  rarefaction,  with  decreased  expression  of  vascular
ndothelial  growth  factor,  could  be  observed  after  pro-
onged  elevated  wall  stress  in  different  models  of  RV  chronic
ysfunction  [61—63].  The  ﬁndings  of  Bogaard  et  al.  also  sup-
ort  the  evidence  that  RV  chronic  pressure  overload  is  not
ufﬁcient  per  se  to  induce  RVF.  Oxidative  stress  within  the
t

p
hJ.  Guihaire  et  al.
V  myocardium  may  be  signiﬁcantly  increased  in  pulmonary
ascular  disease.  The  authors  suggested  that  a  failing  antiox-
dant  defence,  inﬂuenced  by  unknown  mediators  released
y  the  damaged  pulmonary  vasculature,  could  lead  to  RV
ysfunction  [64].
V response to therapy
urrent  drugs  and  emerging  therapies  are  listed  in  Table  3.
n  PH,  three  main  categories  of  medication  are  com-
only  used:  prostanoids,  endothelin  receptor  antagonists
nd  phosphodiesterase  type  5  inhibitors.  A  recent  meta-
nalysis  based  on  pharmacological  randomized  controlled
rials  suggested  an  improvement  in  both  exercise  capac-
ty  and  survival  in  PH  patients  receiving  targeted  therapies
65]. Improvement  of  RV  function  is  poorly  reported  as  a
rimary  endpoint  in  these  trials,  whereas  RVF  remains  the
ain  cause  of  hospitalization  and  mortality  in  patients  with
hronic  cardiopulmonary  disease.  Currently,  there  is  no  ded-
cated  medical  cure  for  RVF.  The  therapies  applied  to  the  LV
re  usually  less  beneﬁcial  for  the  dysfunctional  RV.  More-
ver,  the  beneﬁcial  effects  of  approved  PH  drugs  on  RV
unction  are  mainly  related  to  decreased  afterload.  Direct
ffects  on  the  RV  are  controversial  and  might  be  deleteri-
us.  Nagendran  et  al.  showed  that  myocardial  expression
f  the  endothelin  axis  was  upregulated  in  the  setting  of  RV
ypertrophy,  in  both  humans  and  rats  exposed  to  chronic
H.  These  results  suggested  that  endothelin  receptor  antag-
nists  may  worsen  RV  contractility,  leading  to  irreversible
V  dysfunction  [66].  Long-term  effects  of  prostacyclins  and
ype  5  phosphodiesterase  inhibitors  on  RV  remodelling  are
ot  known.
RV  contractility  usually  compensates  for  the  increased
fterload,  and  RV-PA  uncoupling  occurs  when  RV  afterload
ncreases  much  more  than  RV  contractility.  However,  the
rostanoid  epoprostenol  has  been  associated  with  increased
ortality  at  6  months,  despite  early  improvement  in  exer-
ise  capacity  [67].  The  increase  in  cardiac  output  after  PH
herapy  is  mainly  due  to  the  increase  in  RV  contractility.
his  may  actually  result  in  high  myocardial  oxygen  con-
umption  and  may  therefore  be  detrimental  [68].  van  de
eerdonk  et  al.  reported  a  poor  prognosis  for  PH  patients
ith  impaired  RV  systolic  function  despite  signiﬁcant  pul-
onary  vascular  response  to  therapy  [69]. The  true  effects
f  current  medications  on  ventricular-arterial  coupling  have
een  poorly  investigated.  It  would  be  of  great  interest  if
merging  therapies  improved  RV-PA  coupling  rather  than
ocussing  only  on  RV  contractility.  The  optimal  characteris-
ics  of  a  targeted  therapy  for  RV  dysfunction  are  suggested
n  Table  4.
Adrenergic  stimulation  is  the  main  endogenous  mecha-
ism  for  increasing  cardiac  work  in  the  setting  of  chronic
eart  failure.  Beta-receptor  sensitivity  and  density  are,
owever,  reduced  in  the  hypertrophied  RV  [70].  Ventricu-
ar  chronic  pressure  overload  is  actually  known  to  be  the
rimary  determinant  of  -adrenoreceptor  density  [71,72].
he  recent  ﬁndings  of  Bogaard  et  al.  supported  experimen-
al  beneﬁts  for  RV  remodelling  in  response  to  treatment  with
-adrenergic  blocking  agents,  such  as  carvedilol  and  meto-
rolol.  In  two  different  rat  models  of  chronic  pulmonary
ypertension,  4  weeks  of  treatment  with  beta-receptor
Right  ventricular  pathophysiology  in  chronic  pressure  overload  525
Table  3  Direct  and  afterload-dependent  effects  of  pharmacological  treatments  in  right  ventricular  remodelling:  insights
from  preclinical  animal  models.
Drug  Afterload-independent  effects  Afterload-dependent  effects
PH-targeted  therapies
Phosphodiesterase-5
inhibitors  [80—83]
↑  Mitochondrial  activity
↓  Ventricular  dilatation
↑  Contractility
↓ Myocardial  ﬁbrosis
↑  Capillary  density
↑ Ventricular-arterial  coupling
Prostacyclin  analogues
[84,85]
↑  Capillary  density ↓ Myocardial  ﬁbrosis
↑  Ventricular-arterial  coupling
Endothelin-1  receptor
antagonists  [66,86]
↓  Contractility  ↓  Myocardial  ﬁbrosis
Drugs  used  for  left  ventricular  dysfunction
Levosimendan  [77]  ↑  Contractility  ↑  Ventricular-arterial  coupling
(marked  decreased  in  pulmonary
arterial  elastance)
Beta-blockers  [61]  ↓  Myocardial  ﬁbrosis
↑  Capillary  density
↑ Systolic  function
↓  Ventricular  dilatation
Any  effect  on  pulmonary  circulation
Angiotensin-converting
enzyme  inhibitors  [44]
↓  Myocardial  ﬁbrosis  ↓  Myocardial  hypertrophy
Statins  [87] ↓  ROS  production
↓  Myocardial  inﬂammation
↑  Nitric  oxide  production
Unknown
Blockers  of  the  renin-
angiotensin-aldosterone
axis  [41]
↓  Myocardial  ﬁbrosis  Unknown
Emerging  therapies
Pyruvate  dehydrogenase
kinase  inhibitor
(dichloroacetate)  [56]
↑  Mitochondrial  oxidative  activity  ↑  Exercise  capacity
Antioxidant  (EUK-134)  [88]  ↓  Oxidative  stress
↓  Proapoptotic  signalling
↓  Myocardial  ﬁbrosis
↑  Systolic  function
Any  effect  on  pulmonary  circulation
Multikinase  inhibitors
(sunitinib  and  sorafenib)
[73]
↓  Cellular  hypertrophy
↓ Myocardial  ﬁbrosis
↑  Systolic  function
↓ Cellular  hypertrophy
↓ Myocardial  ﬁbrosis
↑  Systolic  function
Rho-kinase  inhibitor
(fasudil)  [89]
Unknown  ↓  Ventricular  dilatation
↑  Systolic  function
Inhibitors  of  histone
deacetylases  [90]
↓  Cellular  hypertrophy
↓ Capillary  density
↓ Endothelial  and  smooth  muscle
cell  hyperplasia
Selective  pulmonary
SERCA-2a  gene  transfer
[74]
Unknown  ↓  Cellular  hypertrophy
↓ Myocardial  ﬁbrosis
PH: pulmonary hypertension; ROS: reactive oxygen species; SERCA-2a: sarcoplasmic endoplasmic reticular calcium adenosine
triphosphatase 2a.
Table  4  Characteristics  of  the  optimal  drug  to  treat  the  failing  right  ventricle.
Promotion  of  cardiomyocyte  survival
Improvement  in  myocardial  capillary  density
Restoration  of  mitochondrial  activity
Preservation  of  ventricular-arterial  coupling  without  increasing  myocardial  oxygen  consumption
Optimization  of  right  ventricular  preload  and  decreasing  of  right  ventricular  afterload
Prevention  of  myocardial  ﬁbrosis
Control  of  inﬂammatory  response
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lockers  was  associated  with  improvement  in  exercise
ndurance  and  RV  systolic  performance  [61].
Among  the  new  therapeutic  approaches,  metabolic  mod-
lation  might  be  the  most  promising  for  restoration  of
mpaired  mitochondrial  activity  in  chronic  RV  dysfunction,
ncluding  the  use  of  dichloroacetate.  This  orphan  drug,  ini-
ially  employed  in  cancer  therapy,  reduces  the  inhibitory
hosphorylation  of  the  pyruvate  dehydrogenase  complex,
nd  thus  restores  mitochondrial  dysfunction  [56]. The  use
f  multikinase  inhibitors  in  RV  remodelling  has  been  applied
nly  in  experimental  models  of  compensated  RV  hypertro-
hy,  and  not  yet  in  RVF  [73].  Gene  transfer  of  sarcoplasmic
ndoplasmic  reticular  calcium  adenosine  triphosphatase  2a
SERCA-2a)  has  recently  been  demonstrated  to  have  in  vivo
herapeutic  efﬁcacy  in  a  rodent  model  of  chronic  PH,  as
llustrated  by  a  marked  decrease  in  pulmonary  haemody-
amics  and  myocardial  hypertrophy  and  ﬁbrosis  [74].  Other
on-pharmacological  approaches  have  been  suggested  to
arget  the  failing  RV,  including  myocardial  bioengineering,
ardiac  resynchronization  and  RV  mechanical  support.  Fur-
her  experimental  investigations  need  to  be  carried  out  in
he  setting  of  isolated  RV  dysfunction.
onclusion
iven  the  importance  of  RV  function  in  the  prognosis
f  chronic  cardiopulmonary  diseases,  major  experimental
fforts  have  been  made  over  the  last  two  decades  to  improve
ur  knowledge  of  RV  pathophysiology.  A  comprehensive
pproach  in  animal  models  has  led  to  new  pharmacological
reatments,  but  basic  research  has  yet  to  develop  a  targeted
herapy  for  the  failing  RV.  Moreover,  the  question  of  protec-
ive  phenotypes  with  long-term  compensated  hypertrophy
eeds  to  be  addressed.
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